This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Johnson & Johnson

Drug Names(s): JNJ-37822681

Description: JNJ-37822681 is a fast-dissociating dopamine D2 antagonist. It has a moderate D2 affinity (pIC50 6.3) and is highly selective with pIC50 <5 for H1, 5-HT2C or alpha-1 receptors. The design of JNJ-37822681 is based in part on the “fast-off D2” theory, which hypothesizes that antagonists with fast dissociation rates from the D2 receptor will be efficacious but may allow for low incidence of D2-mediated side effects such as hyperprolactinemia and extrapyramidal symptoms.

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug